First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.

被引：0
|
作者：
Andre, Thierry
Elez, Elena
Lenz, Heinz-Josef
Jensen, Lars Henrik
Touchefeu, Yann
Van Cutsem, Eric
Garcia-Carbonero, Rocio
Tougeron, David
Mendez, Guillermo
Schenker, Michael
de la Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Aubin, Francine
Cela, Elvis
Chen, Tian
Lei, Ming
Jin, Lixian
Lonardi, Sara
机构：
[1] Sorbonne Univ, Paris, France
[2] Hop St Antoine, Assistance Publ Hop Paris, Paris, France
[3] Vall Hebron Univ Hosp, Barcelona, Spain
[4] Inst Oncol VHIO, Barcelona, Spain
[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Univ Hosp Southern Denmark, Vejle Hosp, Vejle, Denmark
[7] Ctr Hosp Univ Nantes, Nantes, France
[8] Univ Penn, Philadelphia, PA USA
[9] UCM, Hosp Univ 12 Octubre Imas12, Madrid, Spain
[10] Ctr Hosp Univ Poitiers Site Miletrie, Poitiers, France
[11] Hosp Univ Fdn Favaloro, Buenos Aires, Argentina
[12] Centrul Oncol Sf Nectarie, Craiova, Romania
[13] Univ Med & Pharm, Craiova, Romania
[14] Ctr Leon Berard, Lyon, France
[15] Hosp Univ Virgendel Rocio, Seville, Spain
[16] Natl Canc Ctr Hosp East Kashiwa, Chiba, Japan
[17] Shanghai East Hosp, Shanghai, Peoples R China
[18] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[19] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.LBA143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA143
引用
收藏
页码：LBA143 / LBA143
页数：1
相关论文
共 50 条
  • [11] Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
    Lonardi, S.
    Andre, T.
    Arnold, D.
    Garcia-Carbonero, R.
    Chalabi, M.
    Elez Fernandez, M. E.
    Lenz, H. J.
    Jensen, L. H.
    Joshi, R.
    Roodhart, J. M. L.
    Yoshino, T.
    Dixon, M.
    Blum, S. I.
    Sims, J.
    Lawrance, R.
    Taylor, F.
    Chen, T.
    Cela, E.
    Jin, L.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S1 - S2
  • [12] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
    Van Cutsem, E.
    Dixon, M.
    Taylor, F.
    Sun, X.
    Yip, C.
    Blum, S. I.
    ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553
  • [13] Nivolumab plus ipilimumab combination in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): First report of the full cohort from CheckMate-142.
    Andre, Thierry
    Lonardi, Sara
    Wong, Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Moss, Rebecca Anne
    Ledeine, Jean-Marie
    Cao, Z. Alexander
    Kamble, Shital
    Kopetz, Scott
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [14] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
    Overman, Michael J.
    Lonardi, Sara
    Wong, Ka Yeung Mark
    Lenz, Heinz-Josef
    Gelsomino, Fabio
    Aglietta, Massimo
    Morse, Michael
    Van Cutsem, Eric
    McDermott, Raymond S.
    Hill, Andrew G.
    Sawyer, Michael B.
    Hendlisz, Alain
    Neyns, Bart
    Svrcek, Magali
    Atasoy, Ajlan
    Zhao, Huanyu
    Lei, Ming
    Kopetz, Scott
    Andre, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [15] SAFETY PROFILE OF NIVOLUMAB plus IPILIMUMAB COMBINATION THERAPY IN PATIENTS WITH DNA MISMATCH REPAIR-DEFICIENT/MICROSATELLITE INSTABILITY-HIGH (DMMR/MSI-H) METASTATIC COLORECTAL CANCER (MCRC) IN CHECKMATE-142
    Brutcher, Edith
    Khoukaz, Taline
    Hartman, Leighanne
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [16] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    Yang, Jing
    Ledeine, Jean-Marie
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
    Lenz, Heinz-Josef
    Overman, Michael J.
    Van Cutsem, Eric
    Limon, Maria Luisa
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    McCraith, Stephen
    Wang, Rui
    Lei, Ming
    Yao, Jin
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 97 - 97
  • [18] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
    Lenz, Heinz-Josef
    Overman, Michael J.
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Mark Ka
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Gelsomino, Fabio
    Cardin, Dana Backlund
    Dragovich, Tomislav
    Shah, Usman
    McCraith, Stephen M.
    Wang, Abigail
    Lei, Ming
    Yao, Jin
    Jin, Lixian
    Lonardi, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [19] Nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
    Lenz, Heinz-Josef
    Lonardi, Sara
    Zagonel, Vittorina
    Van Cutsem, Eric
    Limon, M. Luisa
    Wong, Ka Yeung Mark
    Hendlisz, Alain
    Aglietta, Massimo
    Garcia-Alfonso, Pilar
    Neyns, Bart
    Cardin, Dana Backlund
    Spallanzani, Andrea
    Dragovich, Tomislav
    Shah, Usman
    Atasoy, Ajlan
    Ledeine, Jean-Marie
    Overman, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [20] Analysis of tumor PD-L1 expression and biomarkers in relation to clinical activity in patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus ipilimumab (IPI): CheckMate 142
    Andre, T.
    Overman, M.
    Lonardi, S.
    Aglietta, M.
    McDermott, R.
    Wong, K. Y. M.
    Morse, M.
    Hendlisz, A.
    Moss, R. A.
    Ledeine, J-M.
    Tang, H.
    Cao, Z. A.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2017, 28
12345